Evaxion Biotech To Test EVX-03 DNA Vaccine For Non-Small Cell Lung Cancer

  • Evaxion Biotech A/S EVAX has selected EVX-03 as the product candidate within its DNA technology platform to target a new indication with planned regulatory filing in H2 2022.
  • We currently have two product candidates in the DNA technology platform, EVX-02, and EVX-03. Based on preclinical results, the company has decided to move EVX-03 in an upcoming clinical trial in a new indication.
  • EVX-03 is optimized with an APC-targeting unit (Antigen-Presenting Cell), which has shown promising preclinical data, significant tumor reduction at very low doses, and a clear dose-response relationship in all preclinical models.
  • Evaxion has decided to continue the development of EVX-03 in patients with advanced disease and plans to target non-small cell lung cancer (NSCLC) with EVX-03.
  • EVX-02 is currently being tested in a phase 1/2a trial in patients with resectable melanoma. A full clinical readout is expected in Q2 2023.
  • Earlier this month, Evaxion announced an equity purchase agreement with Lincoln Park Capital Fund for up to $40 million of its American Depositary Shares.
  • Price Action: EVAX shares are up 4.55% at $1.84 during the market session on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsPenny StocksHealth CareMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!